A genetic screen of the mutations in the Korean patients with early-onset Alzheimer's disease

• Published in: Clinical interventions in aging 2016-01, Vol.11, p.1817-1822
• Main Authors: An, Seong Soo, Park, Sun Ah, Bagyinszky, Eva, Bae, Sun Oh, Kim, Yoon-Jeong, Im, Ji Young, Park, Kyung Won, Park, Kee Hyung, Kim, Eun-Joo, Jeong, Jee Hyang, Kim, Jong Hun, Han, Hyun Jeong, Choi, Seong Hye, Kim, SangYun
• Format: Article
• Language: English
• Subjects: Age; Aging; Alzheimer Disease - epidemiology; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid beta-Protein Precursor - genetics; Analysis; apolipoprotein-E; Apolipoproteins; Asian Continental Ancestry Group - genetics; Dementia; Development and progression; DNA Mutational Analysis; Families & family life; Family medical history; Female; Genes; Genetic aspects; Genetic testing; Hospitals; Humans; Male; Medical imaging; Middle Aged; Mutation; Neurology; NMR; Nuclear magnetic resonance; Original Research; Patients; Pedigree; presenilin; Presenilin-1 - genetics; Presenilin-2 - genetics; Republic of Korea - epidemiology; Tomography; University colleges
• ISSN: 1178-1998; 1176-9092; 1178-1998
• DOI: 10.2147/CIA.S116724

Early-onset Alzheimer's disease (EOAD) has distinct clinical characteristics in comparison to late-onset Alzheimer's disease (LOAD). The genetic contribution is suggested to be more potent in EOAD. However, the frequency of causative mutations in EOAD could be variable depending on studies. Moreover, no mutation screening study has been performed yet employing large population in Korea. Previously, we reported that the rate of family history of dementia in EOAD patients was 18.7% in a nationwide hospital-based cohort study, the Clinical Research Center for Dementia of South Korea (CREDOS) study. This rate is much lower than in other countries and is even comparable to the frequency of LOAD patients in our country. To understand the genetic characteristics of EOAD in Korea, we screened the common Alzheimer's disease (AD) mutations in the consecutive EOAD subjects from the CREDOS study from April 2012 to February 2014. We checked the sequence of (exons 16-17), (exons 3-12), and (exons 3-12) genes. We identified different causative or probable pathogenic AD mutations, T116I, L226F, and V214L, employing 24 EOAD subjects with a family history and 80 without a family history of dementia. T116I case demonstrated autosomal dominant trait of inheritance, with at least 11 affected individuals over 2 generations. However, there was no family history of dementia within first-degree relation in L226F and V214L cases. Approximately, 55.7% of the EOAD subjects had ε4 allele, while none of the mutation-carrying subjects had the allele. The frequency of genetic mutation in this study is lower compared to the studies from other countries. The study design that was based on nationwide cohort, which minimizes selection bias, is thought to be one of the contributors to the lower frequency of genetic mutation. However, the possibility of the greater likeliness of earlier onset of sporadic AD in Korea cannot be excluded. We suggest early AD onset and not carrying ε4 allele are more reliable factors for predicting an induced genetic mutation than the presence of the family history in Korean EOAD population.